End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
6,540 KRW | +1.24% | -2.53% | +3.81% |
Sep. 04 | CLASSYS Inc. agreed to acquire 17.999971% stake in Ilooda Co., Ltd from Kim Yong Han for KRW40.5 billion. | CI |
Jul. 19 | Bain Capital May Acquire Ilooda for $158m | CI |
Sales 2023 * | 63.3 0.05 | Sales 2024 * | 79.9 0.06 | Capitalization | 133B 101M |
---|---|---|---|---|---|
Net income 2023 * | 10 0.01 | Net income 2024 * | 13 0.01 | EV / Sales 2023 * | 1,86x |
Net cash position 2023 * | 15.5 0.01 | Net cash position 2024 * | 18.7 0.01 | EV / Sales 2024 * | 1,43x |
P/E ratio 2023 * | 12,5x | P/E ratio 2024 * | 9,55x | Employees | 112 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 62.04% |
More Fundamentals
* Assessed data
More news
1 day | +1.24% | ||
1 week | -2.53% | ||
Current month | -4.11% | ||
1 month | -15.50% | ||
3 months | -28.60% | ||
6 months | -13.61% | ||
Current year | +3.81% |
1 week
6 430.00
6 830.00

1 month
6 430.00
7 700.00

Current year
5 480.00
11 530.00

1 year
5 400.00
11 530.00

3 years
4 250.00
11 530.00

5 years
4 250.00
11 530.00

10 years
4 250.00
11 530.00

Managers | Title | Age | Since |
---|---|---|---|
Yong-Han Kim
CEO | Chief Executive Officer | 48 | - |
Hyo-Jae Moon
CTO | Chief Tech/Sci/R&D Officer | 54 | 2014 |
Seung-Yong Park
AUD | Comptroller/Controller/Auditor | 42 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yong-Han Kim
CEO | Chief Executive Officer | 48 | - |
Young-Soo Seol
BRD | Director/Board Member | 54 | 2012 |
Yong-Hyun Yoon
BRD | Director/Board Member | 51 | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-08 | 6,540 | +1.24% | 100,321 |
23-12-07 | 6,460 | -1.07% | 100,590 |
23-12-06 | 6,530 | -0.31% | 91,853 |
23-12-05 | 6,550 | -3.11% | 142,512 |
23-12-04 | 6,760 | +0.75% | 291,266 |
End-of-day quote Korea Stock Exchange, December 07, 2023
More quotes
Ilooda Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medical devices. The Company's main products include medical devices for skin care, medical devices for pigmentation and blood vessels, home and personal beauty devices, dental medical devices, ophthalmic medical devices, and other medical devices. The Company sells its products in domestic and overseas markets.
Calendar
2024-03-14
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.81% | 101 M $ | |
-11.06% | 189 B $ | |
-18.06% | 161 B $ | |
+16.99% | 109 B $ | |
+18.76% | 80 501 M $ | |
+12.86% | 63 269 M $ | |
-6.32% | 49 971 M $ | |
-7.28% | 41 958 M $ | |
-15.00% | 37 158 M $ | |
+17.37% | 31 193 M $ |